China Blood Products Industry Report, 2010-2011

【Abstract】：
 
Recent years have seen fast-growing development of blood product industry in China, with the enterprises concerned numbering 33 which can produce 10-odd blood products including human albumin, human immunoglobulin (pH4) for intravenous injection and human immunoglobulin. In 2003-2010, the CAGR of blood products reached 20.3% in China, far above the global level in the same period.

Thanks to many favorable factors such as the advance of economy and technology, the acceleration of population growth and aging process as well as the people’s further recognition of blood products, China’s blood product market has seen buoyant momentum which is expected to maintain until 2015 and beyond.

However, the blood products of China have always seen short supply due to limited blood plasma source. Especially, since August 2011 when 16 plasma collection stations were closed in Guizhou Province, the production of China-based blood product enterprises has been further constrained.

Accounting for five of the 16 plasma collection stations closed in Guizhou, Hualan Biological Engineering is the biggest victim of the shutdown, but it still comes out top in terms of the number of blood plasma stations (numbering 13), followed by Shanghai RAAS Blood Products and Beijing Tiantan Biological Products Corporation.

The supply shortage of blood products coupled with strained blood plasma source of leading enterprises has propelled China’s import of blood products, but, thus far, only human albumin and recombinant coagulation factor VIII are allowed to import from foreign countries.

Affected by the lower price of human albumin in foreign countries, China has long been increasing its import volume, with the proportion in 2010 reaching 48.4% (by lot release volume), up 7.2% year-on-year. In particular, Octapharma and Behring occupied the biggest chunk.

As for recombinant coagulation factor VIII, due to high price and policy restriction (it’s only allowed to use when hemophilia patients suffer serious bleeding and human coagulation factor VIII is unavailable), only products made by Bayer are allowed to be imported in China. However, considering the scarcity of human coagulation factor VIII and the increasing demand for coagulation factor VIII, the demand for recombinant coagulation factor VIII will grow further in China.

【Table of Contents】 

1. Overview of Blood Product Industry
1.1 Definition of Blood Product
1.2 Classification of Blood Products
1.3 Recombinant Blood Products
1.4 Blood Product Industry Chain
1.5 Features of Blood Products

2. Overview of China Blood Product Industry
2.1 Market Size
2.2 Development Status
2.3 Supply & Demand
2.4 Market Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policies
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export

3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Competition Pattern
3.3 Coagulation Factor
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Competition Pattern
3.8 Rabies Immunoglobulin
3.8.1 Competition Pattern

4. Key Manufacturers in China
4.1 Hualan Biological Engineering Ltd
4.1.1 Profile
4.1.2 Operation
4.1.3 Blood Products
4.2 Shanghai RAAS Blood Products Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Prospects and Trends
4.3 Beijing Tiantan Biological Products Co., Ltd
4.3.1 Profile
4.3.2 Operation
4.3.3 Chengdu Rongsheng Pharmaceuticals Co., Ltd
4.4 China Biologic Products, Inc
4.4.1 Profile
4.4.2 Operation
4.4.3 Shandong Taibang Biological Products Co. Ltd
4.4.4 Xi’an Huitian Blood Products Co. Ltd
4.4.5 Guiyang Qianfeng Biological Product Liability Co., Ltd.
4.5 Jiangxi Boya Biopharmaceutical Co., Ltd
4.5.1 Profile
4.5.2 Operation
4.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
4.6.1 Profile
4.6.2 Operation
4.7 CNBG Shanghai Institute of Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Prospects
4.8 Shanxi Kangbao Biological Product Co., Ltd
4.8.1 Profile
4.8.2 Operation
4.9 Green Cross
4.9.1 Profile
4.9.2 Operation

【Figures & Tables】

Basic Components of Blood
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional
Blood Products
Categories and Comparison of Recombinant Blood Products in China and
Worldwide
Blood Product Industry Chain
Blood Product Market Scale in China, 2003-2015E
Lot Release Volume of Blood Products (by Product) in China,
2007-Jul.2011
Product Structure of Blood Products in China (by Lot Release
Volume), 2009-2010
Annual Plasma Volume in China, 2002-2010
Geographical Distribution of Plasma Collection Station Resources in
China, Aug.2011
Comparison of Per Capita Usage of Blood Products between China and
Developed Countries
Market Share of Major Manufacturers of Blood Products in China, 2010
Comparison among Blood Product Manufacturing Enterprises in China by
Product Line
Production of Blood Product Manufacturing Enterprises in China,
Aug.2011
Global Blood Product Market Scale, 2003-2010 
Blood Products in Overseas Countries
On-going Clinical Trial of New Indications Overseas
Global Blood Product Manufacturing Enterprises
Operation of International Blood Product Giants, 2010
Major Policies for Blood Products in China
Sales and YoY Growth Rate of Biological and Biochemical
Pharmaceuticals in China, 2005-H1 2011 
Supply and Demand of Human Albumin Worldwide, 2010
Ratio of Domestic and Imported Human Albumin in China (by Lot
Release Volume), 2007-2010
Market Share of Major Manufacturers of Domestic Human Albumin (by
Lot Release Volume), 2007-2010
Market Share of Major Manufacturers of Imported Human Albumin (by
Lot Release Volume), 2007-2010
Comparison between China and USA by Consumption of Human
Immunoglobulin (pH4) for Intravenous Injection, 2010
Lot Release Volume and Its Growth Rate of Human Immunoglobulin (pH4)
for Intravenous Injection in China, 2007-2010
Market Share of Major Manufacturers of Human Immunoglobulin (pH4)
for Intravenous Injection (by Lot Release Volume), 2007-2010
Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in
China, 2008-2010
Market Share of Major Manufacturers of Coagulation Factor VIII in
China (by Lot Release Volume), 2008-2010
Comparison between Human-derived Coagulation Factor VIII and
Recombinant Coagulation Factor VIII
Lot Release Volume and Its Growth Rate of Hepatitis B Immunoglobulin
in China, 2008-2010
Market Share of Major Manufacturers of Hepatitis B Immunoglobulin
(by Lot Release Volume), 2008-2010
Release Volume and Its Growth Rate of Human Immunoglobulin in China,
2008-2010
Major Manufacturers and Their Shares in Chinese Human Immunoglobulin
Market (by  Lot Release Volume), 2008-2010
Release Volume and Its Growth Rate of Human Prothrombin Complex in
China, 2008-2010
Manufacturers and Their Shares in Chinese Human Prothrombin Complex
Market (by  Lot Release Volume), 2008-2010
Lot Release Volume and Its Growth Rate of Tetanus Immunoglobulin in
China, 2008-2010
Market Share of Major Manufacturers in Chinese Tetanus
Immunoglobulin Market (by  Lot Release Volume), 2008-2010
Lot Release Volume and Its Growth Rate of Rabies Immunoglobulin in
China, 2008-2010
Market Share of Major Manufacturers in Chinese Rabies Immunoglobulin
Market (by  Lot Release Volume), 2008-2010
Operating Revenue and Net Income of Hualan Biological Engineering
Ltd, 2007-H1 2011 
Operating Revenue of Hualan Biological Engineering Ltd (by Sector),
2007-2010 
Gross Margin of Hualan Biological Engineering Ltd (by Product),
2007-2010
Operating Revenue of Hualan Biological Engineering Ltd (by Region),
2007-2010
Distribution of Plasma Collection Stations of Hualan Biological
Engineering Ltd, Aug.2011
Lot Release Volume of Blood Products of Hualan Biological
Engineering Ltd, 2007-Jul.2011 
Proportion of Blood Products Release Volume of Hualan Biological
Engineering Ltd, 2008-Jul.2011
Operating Revenue of Blood Products of Hualan Biological Engineering
Ltd (by Product), 2007-2010 
Operating Revenue and Net Income of Shanghai RAAS Blood Products
Co., Ltd, 2007-H1 2011 
Operating Revenue of Shanghai RAAS Blood Products Co., Ltd (by
Product), 2005-2010 
Gross Margin of Shanghai RAAS Blood Products Co., Ltd (by Product),
2005-2010
Operating Revenue of Shanghai RAAS Blood Products Co., Ltd (by
Region), 2008-2010 
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products
Co., Ltd, 2007-Jul.2011 
Proportion of Blood Products Release Volume of Shanghai RAAS Blood
Products Co., Ltd, 2007-Jul.2011
Distribution of Plasma Collection Stations of Shanghai RAAS Blood
Products Co., Ltd, Aug.2011
Plasma Volume of Shanghai RAAS Blood Products Co., Ltd, 2007-2011E
Operating Revenue and Net Income of Beijing Tiantan Biological
Products Co., Ltd, 2007-Q1 2011 
Operating Revenue of Beijing Tiantan Biological Products Co., Ltd
(by Product), 2007-2010
Gross Margin of Beijing Tiantan Biological Products Co., Ltd (by
Product), 2007-2010
Operating Revenue of Beijing Tiantan Biological Products Co., Ltd
(by Region), 2007-2010
Operation of Chengdu Rongsheng Pharmaceuticals Co., Ltd, 2008-2009
Lot Release Volume of Blood Products of Chengdu Rongsheng
Pharmaceuticals, 2007-Jul.2011
Proportion of Blood Products Release Volume of Chengdu Rongsheng
Pharmaceuticals Co., Ltd, 2008-Jul.2011
Distribution of Blood Plasma Collection Stations of Chengdu
Rongsheng Pharmaceuticals Co., Ltd, Aug.2011
Operating Revenue and Gross Profit of China Biologic Products, Inc,
2007-H1 2011 
Operating Revenue of Blood Products of China Biologic Products, Inc
(by Product), 2007-2010
Operating Revenue and Total Profit of Shandong Taibang Biological
Products Co. Ltd, 2008-2009 
Lot Release Volume of Blood Products of Shandong Taibang Biological
Products Co. Ltd, 2007-Jul.2011
Operating Revenue and Total Profit of Xi’an Huitian Blood Products
Co. Ltd, 2008-2009
Lot Release Volume of Blood Products of Xi’an Huitian Blood Products
Co. Ltd, 2007-Jul.2011
Operating Revenue and Total Profit of Guiyang Qianfeng Biological
Product Liability Co., Ltd., 2008-2009
Lot Release Volume of Blood Products of Guiyang Qianfeng Biological
Product Liability Co., Ltd., 2007-Jul.2011
Operating Revenue and Net Income of Jiangxi Boya Biopharmaceutical
Co., Ltd., 2008-2010
Operating Revenue of Jiangxi Boya Biopharmaceutical Co., Ltd. (by
Product), 2008-2010
Gross Margin of Jiangxi Boya Biopharmaceutical Co., Ltd. (by
Product), 2008-2010
Prices Trend of Blood Products of Jiangxi Boya Biopharmaceutical by
Product, 2008-2010
Plasma Volume of Plasma Collection Stations of Jiangxi Boya
Biopharmaceutical, 2008-2010
Lot Release Volume of Blood Products of Jiangxi Boya
Biopharmaceutical Co., Ltd., 2007-Jul.2011
R & D Investment and the Proportion in Sales of Jiangxi Boya
Biopharmaceutical, 2008-2010
Blood Product R & D Projects and Progress of Jiangxi Boya
Biopharmaceutical, July 2011
Operating Revenue and Total Profit of Sichuan Yuanda Shuyang
Pharmaceutical Co., Ltd, 2008-2009
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang
Pharmaceutical Co., Ltd, 2007-Jul.2011
Operation of CNBG Shanghai Institute of Biological Products,
2008-2009
Blood Product List of CNBG Shanghai Institute of Biological
Products, Jul.2011
Lot Release Volume of Blood Products of CNBG Shanghai Institute of
Biological Products, 2007-Jul.2011
Distribution of Plasma Collection Stations of CNBG Shanghai
Institute of Biological Products, Aug.2011
Operation of Shanxi Kangbao Biological Products Co., Ltd, 2008-2009
Lot Release Volume of Blood Products of Shanxi Kangbao Biological
Products Co., Ltd, 2007-Jul.2011
Proportion of Blood Products Release Volume of Shanxi Kangbao
Biological Products Co., Ltd, 2008-Jul.2011
Operation of Green Cross (China), 2008-2009
Blood Product List of Green Cross (China), Jul.2011
Lot Release Volume of Blood Products of Green Cross (China),
2007-Jul.2011